MMSI

Business Context and Reporting Period

Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: Merit Medical Systems designs, manufactures, and markets medical devices, primarily for interventional radiology, cardiology, and vascular access. The company reported record revenues for the quarter and six-month period.

Key Financial Metrics

Liquidity & Debt: The company maintained a current ratio of 3.5 to 1. It has $31 million in available lines of credit (Bank of America and Zion's First National Bank) with $0 outstanding as of June 30, 2007. No variable rate debt exists.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 8% ($3.7M) for the quarter and 10% ($9.7M) for the six months compared to the prior year periods. Growth was driven by custom kits, stand-alone devices, and catheters.
• Gross Margin Compression: Gross margins declined from 39.5% to 37.7% (quarter) and 38.7% to 37.3% (six months). Management attributed this to increased wages, additional production headcount, higher sales of lower-margin kits, inventory write-offs, and increased health benefit costs.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased as a percentage of sales (22.9% vs. 23.9% for the quarter) due to operating leverage from sales hires in late 2005. R&D expenses increased slightly due to salary adjustments.
• Acquisitions: Significant asset purchases occurred in the first half of 2007, including the ProGuide catheter assets from Datascope ($3.3M total consideration) and distribution rights for the Kanguru system ($350k). These contributed to goodwill and intangible asset increases.
• Stock Repurchases: The company repurchased 356,884 shares of common stock for approximately $4.2 million during the six-month period.

Guidance, Outlook, and Risks

• Outlook: Management plans to transfer two product lines to a contract manufacturer in Mexico in Q3 2007 to reduce direct labor costs. They intend to move at least one additional line by year-end. The company also plans to launch the newly acquired chronic dialysis catheter, expecting higher margins.
• Tax Matters: The company adopted FIN 48 (Accounting for Uncertainty in Income Taxes) on Jan 1, 2007, resulting in a $610,000 cumulative-effect adjustment reducing retained earnings. The effective tax rate decreased to 35.0% due to new R&D tax credit laws.
• Market Risk: Approximately 11.4% of revenues are denominated in foreign currencies (Euro, GBP, etc.). The company uses forward contracts to hedge exposure but notes that exchange rate fluctuations can impact net income.
• Risk Factors: Key risks include product recalls, regulatory approval delays, competition, healthcare reimbursement changes, and inventory obsolescence. The company maintains an inventory obsolescence reserve of approximately $2.2 million.

Investor Verification Checklist

• Margin Sustainability: Verify if the planned transfer of manufacturing to Mexico successfully reduces labor costs and reverses the gross margin decline trend.
• Acquisition Integration: Monitor the revenue contribution and margin profile of the newly acquired ProGuide catheter and Kanguru distribution rights.
• Inventory Levels: Review future inventory turnover and write-off trends, given the recent write-offs cited as a cause for margin compression.
• Tax Position: Track the resolution of open tax audits (years 2002-2006) and the impact of FIN 48 on future effective tax rates.
• Capital Allocation: Assess the impact of continued stock repurchases on cash reserves relative to capital expenditure needs for expansion.